XBiotech Inc.: MCKENZIE W THORPE amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
McKenzie W. Thorpe amended a Schedule 13G filing with the SEC covering the Thorpe's stake in XBiotech Inc., according to accession number 0001171843-26-007567. The filing updates the investor's previously reported beneficial ownership position in the clinical-stage biotech. Schedule 13G amendments are typically filed when a passive investor's ownership crosses the 5% threshold or changes materially, making the update a signal of shifting institutional interest in the company. The amended disclosure does not itself alter XBiotech's operations or capital structure. Investors will watch for further 13G or 13D filings to gauge whether Thorpe's position is being built up or trimmed.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
XBiotech Inc., McKenzie W Thorpe